17 Results for "

Smo activator

" in MedChemExpress (MCE) Product Catalog:
Products (17)

17 Results for "Smo activator" in MCE Product Catalog:

  • Targets Recommended:
44
44 Publications Verification
Cat. No.: HY-12848
CAS No.: 912545-86-9
Purity:  99.60%
Target:  

Smo

Research Areas:  

Cancer

SAG is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
loading...
    loading...
44
44 Publications Verification
Cat. No.: HY-12848B
CAS No.: 2095432-58-7
Purity:  99.91%
Target:  

Smo

Research Areas:  

Cancer

SAG hydrochloride is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG hydrochloride activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
loading...
    loading...
44
44 Publications Verification
Cat. No.: HY-12848C
CAS No.: 2702366-44-5
Purity:  99.31%
Target:  

Smo

Research Areas:  

Cancer

SAG dihydrochloride is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG dihydrochloride activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-12316
CAS No.: 516-72-3
Purity:  99.29%
Synonyms: 20α-Hydroxycholesterol
20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) is an allosteric activator that selectively targets the Smoothened (Smo) of the Hedgehog pathway with an EC50 of ~30 μM (Hedgehog). 20(S)-Hydroxycholesterol binds to the extracellular cysteine-rich domain (CRD) of Smo in a stereoselective manner, activating downstream Gli transcription factors (without inducing transcription of receptor genes in the Wnt pathway). 20(S)-Hydroxycholesterol enhances osteogenic differentiation of bone marrow stromal cells and synergistically activates the Raf/MEK/ERK pathway with Simvastatin (HY-17502) to promote bone regeneration. 20(S)-Hydroxycholesterol can be used to study the mechanisms of developmental biology, oncology, bone, and angiogenesis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0877
CAS No.: 3093-35-4
Synonyms: SQ-18566
Halcinonide (SQ-18566) is an orally active Smoothened (Smo) agonist. Halcinonide activates the Hedgehog signaling pathway by binding to Smo and promoting its internalization and expression, thereby activating Gli transcription factors. Halcinonide not only stimulates cell proliferation, increases the expression of cyclin D2/CDK6 and inhibits the degradation of caspase-3, but also suppresses Bcl-2/Bax-mediated apoptosis, oxidative stress and inflammatory responses. Halcinonide activates RxRγ to upregulate the expression of myelin genes, thereby reducing cerebral infarction and improving behavioral deficits. Halcinonide has been used in studies related to multiple sclerosis and ischemic stroke .
loading...
    loading...
Cat. No.: HY-B0603
CAS No.: 90566-53-3
Fluticasone is an inhaled corticosteroid used for respiratory research. Fluticasone is a Smo agonist with an IC50 value of 99 nM. Fluticasone activates Hedgehog signaling and promotes the proliferation of primary neuronal stem or precursor cells .
loading...
    loading...
Cat. No.: HY-137115
CAS No.: 334658-24-1
Target:  

Smo

Research Areas:  

Cancer

BODIPY-Cyclopamine is a fluorescently labeled ligand for the Smoothened (SMO) receptor. The activation of SMO is regulated by Patch protein, and over-activated SMO signaling pathways are associated with tumorigenesis. The NanoBRET (Nanofluorescein bioluminescence resonance energy transfer) technique used in the study can sensitively detect the resonance energy transfer between SMO and BODIPY-Cyclopamine, which can be used for high-throughput screening and kinetic analysis. Studying the binding site of BODIPY-Cyclopamine on SMO can also further explore SMO-targeted drugs .
loading...
    loading...
Cat. No.: HY-12848R
CAS No.: 912545-86-9
Target:  

Smo Reference Standards

Research Areas:  

Cancer

SAG (Standard) is the analytical standard of SAG. SAG is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
loading...
    loading...
Cat. No.: HY-12848G
CAS No.: 912545-86-9
SAG (GMP) is SAG (HY-12848) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. SAG is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
loading...
    loading...
Cat. No.: HY-13459
CAS No.: 1373615-35-0
Purity:  99.31%
Target:  

Smo

Research Areas:  

Cancer

PF-5274857 is a potent, selective, orally active and brain-penetrant antagonist of Smo, with an IC50 of 5.8 nM and Ki of 4.6 nM. PF-5274857 has potential for research of tumor types including brain tumors and brain metastasis driven by an activated Hh pathway .
loading...
    loading...
Cat. No.: HY-12848A
CAS No.: 364590-63-6
Target:  

Smo

Research Areas:  

Cancer

(Rac)-SAG is an isoform of SAG (HY-12848). SAG is a potent Smoothened (Smo) receptor agonist (EC50=3 nM; Kd=59 nM). SAG activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .
loading...
    loading...
Cat. No.: HY-12316R
CAS No.: 516-72-3
Synonyms: 20α-Hydroxycholesterol (Standard)
20(S)-Hydroxycholesterol (Standard) is the analytical standard of 20(S)-Hydroxycholesterol. This product is intended for research and analytical applications. 20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC50 of 3 μM in a gene transcription reporter assay using NIH3T3 cells .
loading...
    loading...
Cat. No.: HY-133974
CAS No.: 64907-23-9
Synonyms: 7-keto-25-OHC
Target:  

Smo

Research Areas:  

Cancer

7-keto-25-Hydroxycholesterol (7-keto-25-OHC), a oxysterol, is a Smoothened (Smo) activator. 7-keto-25-Hydroxycholesterol binds to the extracellular cysteine-rich domain (CRD) of Smo .
loading...
    loading...
Cat. No.: HY-13459A
CAS No.: 1613439-62-5
Target:  

Smo

Research Areas:  

Cancer

PF-5274857 hydrochloride is a potent, selective, orally active and brain-penetrant antagonist of Smo, with an IC50 of 5.8 nM and Ki of 4.6 nM. PF-5274857 hydrochloride has potential for research of tumor types including brain tumors and brain metastasis driven by an activated Hh pathway .
loading...
    loading...
Cat. No.: HY-B0603R
CAS No.: 90566-53-3
Fluticasone (Standard) is the analytical standard of Fluticasone. This product is intended for research and analytical applications. Fluticasone is an inhaled corticosteroid used for respiratory research. Fluticasone is a Smo agonist with an IC50 value of 99 nM. Fluticasone activates Hedgehog signaling and promotes the proliferation of primary neuronal stem or precursor cells .
loading...
    loading...
Cat. No.: HY-W338819
CAS No.: 25122-41-2
Clobetasol is a glucocorticoid and Smoothened agonist that can cross the blood-brain barrier. Clobetasol induces Smo-dependent activation of the Shh signaling pathway and nuclear translocation of Gli1. Clobetasol promotes remyelination and reduces myelin loss in lesions of neuromyelitis optica (NMO). Clobetasol may cause adrenal suppression, cushingoid appearance, and local adverse reactions including dysgeusia, xerostomia, and gastroesophageal burning. Clobetasol can be used in research related to neurodegenerative diseases, oral lichen planus, mucous membrane pemphigoid, and neuromyelitis optica .
loading...
    loading...
Cat. No.: HY-184378
CAS No.: 2922221-22-3
Research Areas:  

Metabolic Disease Cancer

MDB5 is a Hedgehog pathway and Smoothened inhibitor that binds to the 7-TM domain of Smo . MDB5 reduces hepatic stellate cell activation, extracellular matrix-related gene expression, collagen deposition, hydroxyproline content and epithelial-mesenchymal transition, and prevents sinusoidal endothelial cell capillarization . MDB5 induces G1 and S phase cell cycle arrest, triggers apoptosis by upregulating Bax and downregulating Bcl-2, and also decreases oxygen consumption rate, glucose uptake, transglutaminase activity and fibronectin matrix assembly . MDB5 reduces the levels of liver injury markers, hepatic triglyceride deposition and hepatic steatosis, restores the tissue structure of the kidney and spleen, and inhibits pancreatic tumor growth without causing body weight loss . MDB5 can be loaded into PEG-PCC-g-DC micelles, achieving high drug loading, sustained release, improved water solubility, enhanced cellular uptake and optimized hepatic distribution, with good tolerance in mice . MDB5 is applicable to research related to alcohol-associated liver disease, liver fibrosis and pancreatic cancer .
loading...
    loading...
  • 1